

b.) Amendment to the Claims

1. (Currently Amended) A recombinant antibody or an antibody fragment ~~thereof~~ thereof, ~~wherein the recombinant antibody or the antibody fragment thereof which~~ specifically binds to human insulin-like growth factor-I (IGF-I) and human insulin-like growth factor-II (IGF-II) to inhibit ~~the biological activities~~ an activity to control proliferation, differentiation and/or apoptosis of epithelial cells of both human IGF-I and human IGF-II and can bind to both human IGF-I and human IGF-II with equivalent strength of affinity.

wherein the VH of the recombinant antibody or the antibody fragment thereof comprises an amino acid sequence consisting of SEQ ID NO:26 and the VL comprises an amino acid sequence consisting of SEQ ID NO:27, 28 or 29.

Claims 2-16 (Cancelled).

17. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ Claim 1, wherein the ~~VH of the recombinant antibody or the antibody fragment thereof comprises an amino acid sequence represented by SEQ ID NO:26 and the VL comprises an amino acid sequence represented by~~ consisting of SEQ ID NO:27.

18. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ Claim 1, wherein the ~~VH of the recombinant antibody or the antibody fragment thereof comprises an amino acid sequence represented by SEQ ID NO:26~~ and the VL comprises an amino acid sequence ~~represented by~~ consisting of SEQ ID NO:28.

19. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ Claim 1, wherein the ~~VH of the recombinant antibody or the antibody fragment thereof comprises an amino acid sequence represented by SEQ ID NO:26~~ and the VL comprises an amino acid sequence ~~represented by~~ consisting of SEQ ID NO:29.

20. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ any one of Claims 1 or 17-19, wherein the recombinant antibody is a human CDR-grafted antibody.

21. (Currently Amended) The recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ any one of Claims 1 or 17-19, wherein the antibody fragment is an antibody fragment selected from Fab, Fab', F(ab')<sub>2</sub>, single-stranded antibody (scFv), dimerized variable region (diabody), disulfide-stabilized variable region (dsFv), and CDR-containing peptide.

Claims 22-24 (Cancelled).

25. (Withdrawn and Currently Amended) A process for producing a recombinant antibody or the antibody fragment thereof according to any one of claims 1 or 17-19, which comprises a step of culturing a transformant obtained by introducing into a host cell an expression vector carrying DNA encoding said recombinant antibody or antibody, fragment thereof ~~the transformant according to Claim 24~~ in a medium to produce the recombinant antibody or the antibody fragment thereof in a culture, and isolating and purifying the recombinant antibody or the antibody fragment thereof from the culture.

26. (Withdrawn and Currently Amended) A medicament which comprises the recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ any one of claims 1 or 17-19 as an active ingredient.

27. (Withdrawn and Currently Amended) A method for treating IGF-associated diseases, which comprises administering a therapeutically effective amount of the recombinant antibody or the antibody fragment thereof according to ~~Claim 5~~ any one of claims 1 or 17-19 to a patient in need thereof.

28. (Withdrawn and Currently Amended) A method according to ~~Claim~~  
~~27~~ any one of claims 1 or 17-19, wherein the IGF-associated diseases are selected from the  
group consisting of cancer, acromegaly and diabetic complications.

Claims 29 and 30 (Cancelled).

31. (New) The recombinant antibody or the antibody fragment thereof  
according to Claim 20, wherein the antibody fragment is an antibody fragment selected  
from Fab, Fab', F(ab')<sub>2</sub>, single-stranded antibody (scFv), dimerized variable region  
(diabody), disulfide-stabilized variable region (dsFv), and CDR-containing peptide.